These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 32682954)

  • 1. Passive immunotherapies targeting Aβ and tau in Alzheimer's disease.
    Plotkin SS; Cashman NR
    Neurobiol Dis; 2020 Oct; 144():105010. PubMed ID: 32682954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's disease Advax(CpG)- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules.
    Davtyan H; Zagorski K; Rajapaksha H; Hovakimyan A; Davtyan A; Petrushina I; Kazarian K; Cribbs DH; Petrovsky N; Agadjanyan MG; Ghochikyan A
    Sci Rep; 2016 Jul; 6():28912. PubMed ID: 27363809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimer's Disease.
    Vander Zanden CM; Chi EY
    J Pharm Sci; 2020 Jan; 109(1):68-73. PubMed ID: 31647950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials.
    Menéndez-González M; Pérez-Piñera P; Martínez-Rivera M; Muñiz AL; Vega JA
    Curr Pharm Des; 2011; 17(5):508-20. PubMed ID: 21375481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end?
    Li Y; Liu Y; Wang Z; Jiang Y
    Expert Opin Biol Ther; 2013 Nov; 13(11):1515-22. PubMed ID: 24053611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-based therapy in Alzheimer's disease.
    Pul R; Dodel R; Stangel M
    Expert Opin Biol Ther; 2011 Mar; 11(3):343-57. PubMed ID: 21261567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapeutic approaches for Alzheimer's disease.
    Wisniewski T; Goñi F
    Neuron; 2015 Mar; 85(6):1162-76. PubMed ID: 25789753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.
    Cribbs DH
    CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):207-16. PubMed ID: 20205639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic versus neuroinflammatory effects of passive immunization is dependent on Aβ/amyloid burden in a transgenic mouse model of Alzheimer's disease.
    Minami SS; Sidahmed E; Aid S; Shimoji M; Niikura T; Mocchetti I; Rebeck GW; Prendergast JS; Dealwis C; Wetzel R; Bosetti F; Matsuoka Y; Hoe HS; Turner RS
    J Neuroinflammation; 2010 Sep; 7():57. PubMed ID: 20920207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advancements toward therapeutic vaccines against Alzheimer's disease.
    Herline K; Drummond E; Wisniewski T
    Expert Rev Vaccines; 2018 Aug; 17(8):707-721. PubMed ID: 30005578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripherally administered sera antibodies recognizing amyloid-β oligomers mitigate Alzheimer's disease-like pathology and cognitive decline in aged 3× Tg-AD mice.
    Wang HC; Yu YZ; Liu S; Zhao M; Xu Q
    Vaccine; 2016 Apr; 34(15):1758-66. PubMed ID: 26945100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of antibodies for immunotherapy of Alzheimer's disease].
    Matsumoto SE; Jin H; Takeda K; Hasegawa Y; Motoi Y; Hattori N; Tabira T
    Rinsho Shinkeigaku; 2012; 52(11):1168-70. PubMed ID: 23196552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for Alzheimer's disease.
    Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
    Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Passive immunotherapy for Alzheimer's disease.
    Guo X; Yan L; Zhang D; Zhao Y
    Ageing Res Rev; 2024 Feb; 94():102192. PubMed ID: 38219962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease.
    Panza F; Frisardi V; Imbimbo BP; D'Onofrio G; Pietrarossa G; Seripa D; Pilotto A; Solfrizzi V
    Immunotherapy; 2010 Nov; 2(6):767-82. PubMed ID: 21091109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural aspects of Alzheimer's disease immunotherapy targeted against amyloid-beta peptide.
    Cehlar O; Skrabana R; Revajova V; Novak M
    Bratisl Lek Listy; 2018; 119(4):201-204. PubMed ID: 29663816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tau passive immunization inhibits not only tau but also Aβ pathology.
    Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
    Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-β-sheet conformation monoclonal antibody reduces tau and Aβ oligomer pathology in an Alzheimer's disease model.
    Goñi F; Martá-Ariza M; Herline K; Peyser D; Boutajangout A; Mehta P; Drummond E; Prelli F; Wisniewski T
    Alzheimers Res Ther; 2018 Jan; 10(1):10. PubMed ID: 29378642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active full-length DNA Aβ
    Rosenberg RN; Fu M; Lambracht-Washington D
    Alzheimers Res Ther; 2018 Nov; 10(1):115. PubMed ID: 30454039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.